• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2023 Fiscal Year Final Research Report

Strategic creation of polymer-lipid hybrid nanoparticles for tissue-selective nucleic acid delivery

Research Project

  • PDF
Project/Area Number 22K19907
Research Category

Grant-in-Aid for Challenging Research (Exploratory)

Allocation TypeMulti-year Fund
Review Section Medium-sized Section 90:Biomedical engineering and related fields
Research InstitutionHokkaido University

Principal Investigator

Isono Takuya  北海道大学, 工学研究院, 准教授 (70740075)

Co-Investigator(Kenkyū-buntansha) 原島 秀吉  北海道大学, 薬学研究院, 教授 (00183567)
佐藤 悠介  北海道大学, 薬学研究院, 助教 (10735624)
佐藤 敏文  北海道大学, 工学研究院, 教授 (80291235)
Project Period (FY) 2022-06-30 – 2024-03-31
Keywords核酸医薬 / ドラッグデリバリーシステム / 精密重合
Outline of Final Research Achievements

In this study, structurally and physicochemically diverse amino-functionalized polyesters (APEs) were precisely synthesized, aiming to create nanocarriers capable of selectively delivering nucleic acids to various major organs through screening of APE-based polymer-lipid hybrid nanoparticles (PLNPs). Specifically, APEs were synthesized via ring-opening polymerization of caprolactone derivatives using aminoalcohols. A library comprising over 100 variants was constructed by varying initiators, monomers, and degrees of polymerization. Among them, several PLNPs incorporating APE components demonstrated selectivity towards the lungs and spleen. Additionally, the ring-opening alternating copolymerization of glycidylamine and cyclic anhydrides was explored as a method to construct a novel APE library.

Free Research Field

高分子化学

Academic Significance and Societal Importance of the Research Achievements

狙った組織への選択的な核酸デリバリーの実現は、DDS分野における大きな課題である。各臓器・組織を狙い撃ちできる優れたキャリアをひとたび得ることが出来れば、内包する核酸の選択次第で従来治療が困難であった遺伝子疾患、がん、ウイルス感染症など多岐にわたる疾病に対する治療法確立に直結する。また、組織選択性を極限まで高めることは副作用を低減するだけでなく、高価な核酸の投与量を減らすことに繋がり、安全かつ安価な核酸医薬を患者へ提供できる。このように本研究で提案したキャリア創出の方法論は将来的に、核酸医薬の実用化と治療対象疾患の拡大に貢献するものと期待される。

URL: 

Published: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi